Cardiol Therapeutics Inc. (TSE:CRDL) Senior Officer Purchases C$35,606.69 in Stock

Cardiol Therapeutics Inc. (TSE:CRDL) Senior Officer Andrew Warwick Hamer bought 18,900 shares of the stock in a transaction dated Thursday, December 19th. The shares were bought at an average price of C$1.88 per share, for a total transaction of C$35,606.69.

Cardiol Therapeutics Price Performance

TSE:CRDL opened at C$1.81 on Friday. The stock has a 50 day moving average price of C$2.31 and a 200 day moving average price of C$2.65. The stock has a market cap of C$126.48 million, a PE ratio of -4.11 and a beta of 0.70. The company has a debt-to-equity ratio of 1.07, a quick ratio of 6.84 and a current ratio of 2.39. Cardiol Therapeutics Inc. has a one year low of C$1.09 and a one year high of C$4.26.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.